

#### **BEST OF ASCO**

Annual Meeting 2021 Riyadh - Alfaisal University

### PROGRAM



## ELCOME

M E S S A G E





This conference represents a Joint Meeting and Exhibition ASCO meeting in the Kingdom of Saudi Arabia and I am truly amazed at the progress we have made in this medical field by standard of care that helps us take better care of our oncology patients in Saudi Arabia.

The respective chairs for both Scientific and Organizing

Committees have worked diligently in spite of the rise of a global pandemic that hit the world by storm but members forming these committees and staff managed to organize such an important event for this year.

The ASCO mission in the kingdom is to defeat cancer through research and education promoting the highest quality patient care possible. We envision our country where cancer is prevented or cured and that every survivor is healthy and fit. As a Chairman this year, I have had the opportunity to observe firsthand the various things ASCO does all over the world to make a difference in cancer care and I cannot wait to share them over the next few days.

Annual meeting attendees in the kingdom will continue to find the sophisticated scientific presentations and comprehensive educational content that they expect and will also see some variations to the Meeting program taking better care to all our patients with cancer is our ultimate goal. I personally guarantee that your attendance in this November's Annual Meeting will help make a difference in cancer care.

Thanks for attending and for your participation and if we both get the chance, I am looking forward to meet with you personally at the venue.

Yours truly,



## BOARD MEMBERS



#### EXECUTIVE BOARD MEMBERS



DR. AHMED ALLEHEBI Consultant Medical Oncology King Faisal Hospital & Research Center – Jeddah



DR. BASSAM BASULAIMAN
Consultant Medical Oncologist at King
Fahad Medical City



DR. KANOAN AL-SHAMMARI

Medical Oncology Consultant – CI, sarcoma

Department of Medical Oncology

King Abdulaziz Medical City



DR. ALI AL-ZAHRANI
Consultant medical oncologist
King fahad medical city



DR. WALEED ALSELWI Consultant Medical Oncology ,King Fahad Specialist Hospital –Dammam



DR. MOHAMMAD AL-GHAMDI

Medical oncologist - Deputy director and head of
medical oncology unit. Oncology center
King Saud University Medical City



DR. AHMAD AL-SHEHRI

Master of Medical Education King Saud
Bin Abdulaziz University for Health
Sciences



DR. AHMAD AL-ZAHRANI
Consultant medical oncologist



**DR. FAHAD BIN SHAMSAH**Chairman Scientific Committee, Chairman, adult Medical Oncology King Fahad Specialist Hospital



#### CHAIRMEN & SPEAKERS



DR. IBRAHIM MADKALI Medical oncology consultant Prince Mohammed bin Nasser Hospital



DR. HAZEM ALOTIBI consultant of medical oncology and internal medicine Chairman of Hail Oncology Centre



DR. TURKY ALFAEEA Consultant medical oncologis King Abdulaziz Medical City-Jeddah



DR. AMIN ALTEGANI



DR. SHOUGI BAZABASHI Consultant Medical Oncology.



DR. OMAR ALSHAER Consultant Medical Oncology Security Forces Hospital



DR. MARWAN ALHAJILI CONSULTANT, Head of Oncology Division King Abdulaziz University Jeddah, Saudi Arabia.



DR. AHMED BATHEEB Professor of Internal Medicine & Medical Oncology at King Khalid Hospital – Najran, Saudi Arabia.



DR. SHADI KHAIYAT Consultant in Internal Medicine and Medical Oncology



PROF. MOHAMED ABDULWARTH Professor of medical oncology Ex head of medical oncology King Saud university medical city



DR. IBRAHIM ALOTAIN Radiation oncologist, at king Fahad specialist hospital Dammam



DR. RIYAD DADA senior consultant at KFSHRC-Jeddah where he has established and leading as Director the lymphoma program



DR. ABDULAZIZ AL HAMAD Chairman, Department of Oncology Prince Sultan Military Medical City Riyadh, Saudi Arabia



DR. AHMED SAAD ALDAEEN Consultant Adult Clinical Oncologist & Education Supervisor Department of Oncology, King Abdullah Specialized Children's Hospital-MNGHA



**DR. ADHAR ALSAYED** Section of Medical Oncology Oncology Centre King Faisal Specialist Hospital & Research Centre (KFSH&RC) Riyadh, Kingdom of Saudi Arabia



DR. SHAREEF ALSAMANI Associate Consultant of Medical Oncology, King Abdullah Medical City, Makkah



DR. HASHEM ALHASHEM

Consultant, Medical Oncology Director, Adult Medical Oncology Fellowship Program King Saud Medical City, Riyadh



DR. MOHMED RAHAL

Consultant medical oncologist , KFSH-Dammam



DR. MERVAT MEHROUS

Oncology consultant Prince Sultan Military Medical city Riyadh Associate professor of oncology.



DR. NAFISSA ABDEL HAFEZ

Consultant of Medical Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia



DR. RASHA SALIH consultant medical oncologist with interest in Gynaecological & GI malignancy in KKUH Riyadh



DR. SAJJID DURRANI
A Fellow of Royal College of London with
expertise in Breast Cancer and
Gynecology malignancies



DR. BASSAM BASULAIMAN

Medical Oncology Consultant King Fahad Medical City – Riyadh



DR. SAMAH AL RUHALI

Consultant Medical oncologist Lung and Gl at Princess Noorah Oncology Center , KAMC Jeddah



DR. IBRAHIM AL-GORASHI
Consultant in Medical Oncology that specializes in Gastrointestinal Malignancies

PROF. JEAN-MARC NABHOLTZ

King Saud medical city | KSMC -Department of Oncology Professor of Medicine



DR. ALI AL-FAKEEH

Consultant Medical Oncologist who is currently working as the Chairman of Medical Oncology



DR. HATOON BAKHRIBAH

Consultant Medical Oncologist at King Fahad Medical City (KFMC) Riyadh

DR. WALEED AL-GHAREEB

Consultant medical oncologist



DR. FAISAL ALBADINAH

Consultant medical oncologist King Abdullah medical city



DR. MOHAMED GARNI

CONSULTANT, MEDICAL ONCOLOGY.



DR. HUDA AL-ABDULKARIM

Consultant Oncology at the unit of hematology / oncology unit



DR. JAMAL ZEKRI

Professor of Medicine, Al Faisal University Consultant Medical Oncologist King Faisal Specialist Hospital & Research Centre



DR. MUBARAK ALMANSOUR

Consultant, Adult Medical Oncology Oncology Department, Princess Noorah Oncology Center



DR. OMALKHAIR ABULKHAIR

Medical Oncologist at Dr. Sulaiman Al Habib Medical Center



DR. MOHAMMAD AL-GHAMDI

Medical oncologist, Deputy director and head of medical oncology unit. Oncology center King Saud University Medical City



DR. ESSAM MURSHED

Consultant clinical oncologist oncology center, prince sultan medical military city Riyadh



DR. METEB ALFOHEIDI

Medical Oncology Consultant Breast Cancer Sub-specialty



DR. FAISAL AZAM

FRCP consultant medical oncologist King Fahad specialist hospital Dammam



DR. AHMED ALWABARI

Assistant Professor At University Of Arkansas For Medical Sciences American Board Of Internal Medicine, Hematology And Oncology



DR. ABDULRAHEEM ALSHANGETI

Medical oncologist FRCPC



DR. ABDULLAH AL-TWAIRQI

Consultant Medical Oncologist at the Comprehensive Cancer Center, King Fahad Medical City in Riyadh



DR. EMAD TASHKANDI

Medical Oncologist, Assistant Professor, Umm AlQura University SCIENTIFIC

## PRO GRAM

DAY 1 - 26 NOVEMBER,



TIME	TOPIC	SPEAKER
SESSION I	- BREAST CANCER	
CHAIRMAN	t Dr. Shareef Elsamani - Dr.Adher Alsayed - Dr. Ahmed	d Saad Aldaeen
13:00-13:10	OPENING CEREMONY	DR. ABDULLAH ALSHARM
13:10-13:25	A phase III, multicenter,randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer	DR. HUDA ALBDULKAREEM
13:25-13:40	A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131	DR. METAB ALFAHIDI
13:40-13:55	De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.	DR. OMALKHAIR ABOALKHAII
13:55-14:10	Breast Cancer Index (BCI) and Prediction of Benefit from Extended Aromatase Inhibitor (AI) Therapy (tx) in HR+ Breast Cancer: NRG Oncology/NSABP B-42. Trastuzumab Plus Endocrine Therapy or Chemotherapy as first-line Treatment for Metastatic Breast Cancer with Hormone Receptor-Positive and HER2-positive: The Sysucc-002 Randomized Clinical Trial.	DR. AHMED ALWABARI
14:10-14:35	Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.	DR. JEAN NABHOLTZ
14:35-14:45	DISCUSSION	
14:45-15:15	COFFEE BREAK ( PRAYER )	
SESSION I	I - HEAD AND NECK CANCER	
CHAIRMAN	l: Dr. Abdulaziz Alhamed - Dr. Riyad DADA - Dr. Ibrah	nim Alotien
15:15-15:30	Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase III trial.	DR. MOHMED RAHAL
15:30-15:45	Cabozantinib versus placebo in patients withradioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial	DR. FASIAL ALBIDINAH
15:45-16:00	Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial	DR. IBRAHIM ALGORASHI
16:00-16:10	DISCUSSION	
SESSION I	II - MUSCULOSKELETAL CANCER / SKIN / CNS	CANCER
CHAIRMAN	Prof. Mohamed Abdularath - Dr. Shadi khaiyat	
16:10-16:25	Neoadjuvant & adjuvant Nivolumab with anti-LAG3 antibody relatlimab for patients with resectable clinical stage III melanoma	DR. HATTON BAKHARIBAH
16:25-16:40	Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors	DR. ALI FAGEH
	SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma	DR. WALEED ALGHAREEB
16:40-16:55		
16:40-16:55	A phase III study (APROMISS) of AL3818 (Catequentinib Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma	DR. KANAN ALSHAMRI

SCIENTIFIC

## PRO GRAM

DAY 2 - 27 NOVEMBER,



. 9		
TIME	TOPIC	SPEAKER
SESSION I	V - GASTROINTESTINAL CANCER	
CHAIRMAN	Dr. Ahmed Alzahrani - Dr. Ali Alzahrani - Dr. Faisal	ALBadinah
8:00 - 8:10	Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer.	DR. ABDURAHEM ALSHENGET
8:10 - 8:20	Trastuzumab deruxtecan (T-DXd; DS-8201)in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, openlabel study (DESTINY-CRC01).	DR. FAHED BIN SHAMSA
8:20 - 8:30	The TRUSTY study: A randomized phase 2/3 study of trifluridine/ tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.	DR. MOHEMD ALGARNI
8:30 - 8:40	Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded efficacy and safety analyses from CheckMate 577	DR. SAMAH AL RUHALI
8:40 - 8:50	Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.	DR. HASHEM ALHASHEM
8:50 - 9:00	First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/ gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.	DR. EMAD TASHKANDI
9:00 - 9:30	SATELLITE ( MERCK )	
9:30 - 9:40	DISCUSSION	
SESSION II	V – GYNAECOLOGICAL CANCER	
	Dr. Ahmed Batheeb - Dr. Marwan Alhajili - Dr. Om	ar Alshaer
9:40-9:55	Efficacy and safety results from neopembrov study, a randomized phase II trial of neoadjuvant chemotherapy (CT) with or without pembrolizumab (P) followed by interval debulking surgery and standard systemic therapy ± P for advanced high-grade serous carcinoma (HGSC): A GINECO study	DR. BASSAM BASULAIMAN
9:55-10:10	Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).	DR. WALEED ALSALWI
10:10-10:25	Pertuzumab plus trastuzumab (P+T) in patients (Pts) with uterine cancer (UC) with ERBB2 or ERBB3 ampli fication, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.	DR. SAJID DURRANI
10:25-10:40	Intensive versus minimalist follow-up in patients treated for endometrial cancer: A multicentric randomized controlled trial (The TOTEM study—NCT00916708).	DR. RASHA SALAH
10:40-10:50	DISCUSSION	

TIME	TOPIC	SPEAKER
SESSION 6	- GENITOURINARY CANCER	
CHAIRMAN	🕻 Dr. Shougi bazabashi - Dr. Amin Altegani - 🛛 Dr. Ess	am Murshed
10:50-11:05	Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.	DR. JAMAL ZEKRI
11:05-11:35	SATELLITE (IPSEN) Advanced in Renal Cell Carcinoma Management From Biology to Treatment Approaches	SPEAKER: DR. RANA R. MCKAY CHAIRMAN: DR. FAHAD BINSHAMSA
11:35-11:50	Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).	DR. FEISAL AZAM
11:50-12:20	SATELLITE (ASTRAZENECA): The Backbone of Prostate Cancer Management	SPEAKER: DR. BASSAM BASULAIMAN CHAIRMAN: DR. MOHAMMED ALGHAMDY
12:20-12:50	SATELLITE (JANSSEN) Management updates in mHSPC	SPEAKER: DR. FAISAL AZAM CHAIRMAN: DR. MOHAMEMED ALGHAMDI
12:50-13:20	BREAK ( LAUNCH )	
13:20-13:35	SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).	DR. MOHMED ALGHAMDI
13:35-13:50	A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.	DR. MUBARK ALMANSOUR
13:50-14:20	SATELLITE (MSD) Role of IO in 1L RCC Management	SPEAKER: DR. FAISAL AL BADAINAH CHAIRMAN: DR. EMAD TASHKANDI
14:20-14:50	SATELLITE (ASTELLAS) Updates of M1 CRPC Management	SPEAKER: DR. FAISAL ALBADAINAH
SESSION 7	- LUNG CANCER	
CHAIRMAN	🕻 Dr. Turky Alfaeea - Dr. Hazem Alotibi - Dr. Ibrahim	Madkali
14:50-15:05	Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).	DR. AHMED ALLUHAIBI
15:05-15:20	IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).	DR. NAFISSA ABDEL HAFEZ
15:20-15:50	SATELLITE SYMPOSIUM ( BMS ) Evolution in treating cancers in Era of Dual IO blockade	SPEAKER: DR. SHADY AL KHAYAT
15:50-16:20	SATELLITE SYMPOSIUM ( BMS ) New strategy in treating 1L NSCLC in era of dual IO blockade	SPEAKER: DR. AHMED ALEHEBI
16:20-16:35	BREAK	
16:35-16:50	Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.	DR. ABDULLAH ALTWERQI
16:50-17:05	First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.	DR. MERVAT MEHROUS
17:05-17:15	DISCUSSION	

## S P O N S O R COMPANY





LYNPARZA (Tablets 150mg & 100mg)
NOW APPROVED

In Saudi Arabia for

Treatment of adult patients with germline BRCA1/2 mutation, who have HER-2-negative Locally Advanced or metastatic Breast Cancer.1

DARI

REIMAGINE

AstraZeneca 🕏

For modelet information.

For modelet information.

For the Market Tensor - From USA, the Treasuresh Found - A. Reinste Debret - 7190. Use the 20 Fepade 13016 - 250 for information - From USA, the Treasuresh Found - A. Reinste Debret - 7190. Use the 20 Fepade 13016 - 250 for information - From USA, the Conference of the Section - 7190. Use the 20 Fepade 13016 - 250 for information - 7190.

"I- Ipaparea serimory of product characteristics, afdingenion



LYNPARZA (Tablets 150mg & 100mg)
NOW APPROVED

#### In Saudi Arabia for

Maintenance treatment of patients with BRCA mutated ovarian cancer following response to first-line platinum-based chemotherapy.<sup>1</sup>

AstraZeneca 🕏

Necessary Control of the Control of

\*1- Lynparza summary of product characteristics, sfda.gov.sa

**ZOLADEX®:-**SUPPORTING HEALTHCARE
PROFESSIONALS AND THEIR PATIENTS



#### BY PRESCRIBING ZOLADEX®, YOU CAN:

Expect efficacy across the disease continuum Zoladex® has proven survival benefits in all 3 clinical settings of prostate cancer, high rick localized locally. high risk localised, locally advanced and metastatic. 1-5

#### Make no assumptions on class-effect

More supporting evidence in prostate cancer than any other LHRHa.6

Benefit from its versatility The 3.6 mg dose offers a range of additional indications, refer to Zoladex® SmPC for full details.<sup>7</sup>



AstraZeneca 🕏

GROWING CLINICAL EXPERIENCE IN PROSTATE CANCER MANAGEMENT

**Zolade**x°





### **PUSH BACK EARLY.**

By using ERLEADA® + ADT early, you can improve overall survival and delay disease progression for longer than placebo + ADT, while keeping other treatments for later stages. 1-3 ERLEADA® + ADT:

- Reduced risk of death by 35% vs. placebo + ADT, and by nearly half (48%) after adjusting for crossover<sup>2</sup>
- Significantly improved rPFS with 68.2% of patients with radiological progression free-survival at 2 years vs. 47.5% in the placebo + ADT group<sup>3‡</sup>

TREAT EARLY WITH ERLEADA® PUSH BACK ON PROGRESSION<sup>2</sup>



nce interval. HR, hazard ratio. mHSPC, metastatic horm ographic progression-free survival. nen for the treatment of metastatic hormone-sensitive

ADT.:
DIT: the majority of patients were still alive at the time of the
HB: 0.52 (95% Ci: 0.42-0.64) p<0.0001.<sup>2</sup>
;-based documentation of progressive disease or death,
or be estimated for ERLEADA\* + ADT vs. 22.1 months with



PHARMACEUTICAL COMPANIES OF Johnson Johnson

Date of preparation: August 2021 CP-256920




# KEYTRUDA® Sets new survival expectations in multiple tumor types¹





KEYTRUDA® sets new survival expectations in multiple tumor types<sup>1</sup>







**CABOMETYX®** is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy<sup>1</sup>



'PFS analysis population; ITT population; Partial responses only

Please insert abbreviated SmPC



CABOMETYX® SmPC, July 2016
 Choueiri TK, Escudier B, Powles T, et al. N Engl J Med 2015;373:1814-23

<sup>3.</sup> Choueiri TK, et al. Lancet Oncol 2016;17:917-27



3. Beer TM et al.. Eur Urol. 2017; 71:151-4.

1. XTANDI Summary of Product Characteristics, Xtandi NM\_SmPC

2. Hussain *M et al. NEJM.* 2018; 378:2465-74.

3. Beer TM et al. Eur Urol. 2017; 71:151-4. For any medical information related to Xtandi ™, please contact: medicalinformation menassa@astellas.com Incase of any suspected adverse events or any safety information associated with Xtandi ™, please report immediately to: email: pharmacovigilance.ae@astellas.comTel: +966-11-2933024 /+966-11-4631890 Date of preparation: Feb 20 / Country of intended use: Saudi Arabia / XTD\_2020\_0006\_SA



Ask your doctor about the treatment options of Multiple Myloma Lenalidomide SPC is a treatment for:

Newly diagnosed multiple myeloma — in patients who have had a bone marrow transplant lenalidomide SPC is used on its own as maintenance therapy after patients have recovered enough following a bone marrow transplant.

Newly diagnosed multiple myeloma — in patients who cannot have a bone marrow transplant lenalidomide SPC is taken with other medicines:

a chemotherpay medicine called 'Bortezomib' • an anti-inflammatory medicine called
'dexamethasone' • a chemotherapy medicine called 'melphalan' and, • an immunosuppressant
medicine called 'prednisone'. You will take these other medicines at the start of treatment and then
continue to take lenalidomide SPC on its own. If you are aged 75 years or older or have moderate to
severe kidney problems - your doctor will check you carefully before starting treatment.

Multiple myeloma — in patients who have had treatment before lenalidomide SPC is taken together with an anti-inflammatory medicine called 'dexamethasone'. Lenalidomide SPC can stop the signs and symptoms of multiple myeloma getting worse. It has also been shown to delay multiple myeloma from coming back following treatment.



Lenalidomide SPC®

5 mg - 10 mg - 25 mg capsule





## RESP NSE

That offers a median progression free survival of >18 months in RAI refractory DTC patients<sup>1</sup>

That prolonged the median progression free survival vs. Sorafenib in unresectable HCC (7.4 vs 3.7 months; HR: 0.66, 95% CI: 0.57–0.77; p<0.0001)<sup>2</sup>

#### Indications:

- Monotherapy treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/ follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
- Monotherapy treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.

Please refer to the Summary of Product Characteristics before prescribing. In the event of an adverse event occurring from any of the NewBridge licensed products, kindly report them to the NewBridge Safety Mailbox at safety@nbpharma.com.

#### Reference:

- Schlumberger M, et al. N Engl J Med 630-372:621;2015.
- Kudo M et al. Lancet 2018;391:1163-1173.

























